title: Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy.
abstract: OBJECTIVE
  The aim of this study was to evaluate the salvage radiotherapy outcome in patients with local recurrent esophageal cancer after radical radiochemotherapy (RCT).
  
  
  METHODS
  A total of 114 patients with local recurrent esophageal squamous cell carcinoma after initial radical RCT were retrospectively analyzed. Fifty-five (55) patients belonged to the salvage radiotherapy group (SR group) and 59 patients to the non-salvage radiotherapy group (NSR group).
  
  
  RESULTS
  The median survival time after-recurrence was 4 months in all patients. The 1, 2, 3 year overall survival (OS) rates were 83.6%, 41.8% and 21.8% respectively in the SR group, and 57.6%, 16.9%, and 8.5% in the NSR group. The 6-month and 1-year survival rates after-recurrence were 41.8% and 16.4% respectively in the SR group, and 11.9% and 3.4% respectively in the NSR group. A salvage radiation dose > 50 Gy after initial radical RCT, improved the survival of patients with local recurrent esophageal cancer. Three patients (5.45%) from the SR group showed more than 3-grade radiation pneumonitis. In addition, esophageal fistula/perforation was observed in 11 cases (20.0%) in the SR group and in 8 cases (13.6%) in the NSR group.
  
  
  CONCLUSIONS
  Salvage treatment after definitive RCT may improve the overall survival and survival after-recurrence of patients with local recurrent esophageal cancer.
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, China. chenk777@126.com.|Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. chenk777@126.com.
authors.forename: Zhi-guo
authors.initials: ZG
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. 1026609441@qq.com.
authors.forename: Chan-jun
authors.initials: CJ
authors.lastname: Zhen
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. 284479739@qq.com.
authors.forename: Wen-wen
authors.initials: WW
authors.lastname: Bai
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. zpsjz@sohu.com.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. xueying_qiao@126.com.
authors.forename: Xue-ying
authors.initials: XY
authors.lastname: Qiao
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. nienannan@126.com.
authors.forename: Jun-li
authors.initials: JL
authors.lastname: Liang
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, China. gaoxianshu777@126.com.
authors.forename: Xian-shu
authors.initials: XS
authors.lastname: Gao
authors.affiliation: Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. zhou_pr@sohu.com.
authors.forename: Shuo-shuo
authors.initials: SS
authors.lastname: Wang
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate